A. Balkrishna, P. Thakur, Shivam Singh, Namita Singh, A. Tanwar, R. Sharma
{"title":"In silico screening for investigating the potential activity of phytoligands against SARS-CoV-2","authors":"A. Balkrishna, P. Thakur, Shivam Singh, Namita Singh, A. Tanwar, R. Sharma","doi":"10.36069/JOLS/20210302","DOIUrl":null,"url":null,"abstract":"SARS-CoV-2 causes COVID-19, a life-threatening respiratory illness with high rates of morbidity and mortality. As of date, there is no specific medicine to treat COVID-19. Therefore, there is an acute need to identify evidence-based holistic and safe mitigators. The present study aims to screen phytochemicals based on bioprospection analysis and subsequently predicting their binding potential to SARS-CoV-2 proteins in silico. The drug likeliness and ADMETox descriptors of 24 phytoligands were computationally predicted. Docking studies were further conducted with those phytoligands that qualified the drug likeliness parameters. Docking studies suggested that the herbal moiety, namely, gamma-glutamyl-S-allylcysteine demonstrated highly significant binding energies with viral spike glycoprotein, endoribonuclease, and main protease (binding energy ≥ -490 kcal/mol for all the tested target viral proteins). Gamma-glutamyl-S-allylcysteine demonstrated more significant binding potential as compared to the known chemical analog, i.e., hydroxychloroquine, as observed in the computational docking studies. This study serves to present pre-eminent information for further clinical studies highlighting the utility of herbal ligands as probable lead molecules for mitigating novel Coronavirus infection.","PeriodicalId":87302,"journal":{"name":"Journal of life sciences (Westlake Village, Calif.)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of life sciences (Westlake Village, Calif.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36069/JOLS/20210302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
SARS-CoV-2 causes COVID-19, a life-threatening respiratory illness with high rates of morbidity and mortality. As of date, there is no specific medicine to treat COVID-19. Therefore, there is an acute need to identify evidence-based holistic and safe mitigators. The present study aims to screen phytochemicals based on bioprospection analysis and subsequently predicting their binding potential to SARS-CoV-2 proteins in silico. The drug likeliness and ADMETox descriptors of 24 phytoligands were computationally predicted. Docking studies were further conducted with those phytoligands that qualified the drug likeliness parameters. Docking studies suggested that the herbal moiety, namely, gamma-glutamyl-S-allylcysteine demonstrated highly significant binding energies with viral spike glycoprotein, endoribonuclease, and main protease (binding energy ≥ -490 kcal/mol for all the tested target viral proteins). Gamma-glutamyl-S-allylcysteine demonstrated more significant binding potential as compared to the known chemical analog, i.e., hydroxychloroquine, as observed in the computational docking studies. This study serves to present pre-eminent information for further clinical studies highlighting the utility of herbal ligands as probable lead molecules for mitigating novel Coronavirus infection.
SARS-CoV-2会导致COVID-19,这是一种危及生命的呼吸系统疾病,发病率和死亡率都很高。到目前为止,还没有治疗COVID-19的特异性药物。因此,迫切需要确定以证据为基础的全面和安全的缓解措施。本研究旨在基于生物前景分析筛选植物化学物质,并随后预测其与SARS-CoV-2蛋白的结合潜力。对24种植物配体的药物似然性和ADMETox描述符进行了计算预测。进一步与符合药物似然参数的植物配体进行对接研究。对接研究表明,草药部分,即γ -谷氨酰胺- s -丙氨酸半胱氨酸与病毒刺突糖蛋白、核糖核酸内切酶和主要蛋白酶的结合能非常显著(所有测试的目标病毒蛋白的结合能均≥-490 kcal/mol)。在计算对接研究中观察到,与已知的化学类似物,即羟氯喹相比,γ -谷氨酰- s -丙氨酸半胱氨酸表现出更显著的结合潜力。本研究为进一步的临床研究提供了卓越的信息,突出了草药配体作为减轻新型冠状病毒感染的可能铅分子的效用。